Immune Checkpoint Inhibitor-Induced Myasthenia Gravis

The development of immune checkpoint inhibitors (ICIs) has been a major breakthrough in cancer immunotherapy. The increasing use of ICIs has led to the discovery of a broad spectrum of immune-related adverse events (irAEs). Immune-related myasthenia gravis (irMG) is a rare but life-threatening irAE....

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yi-Te, Chen, Ya-Ping, Lin, Wen-Chih, Su, Wu-Chou, Sun, Yuan-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378376/
https://www.ncbi.nlm.nih.gov/pubmed/32765397
http://dx.doi.org/10.3389/fneur.2020.00634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378376/
https://www.ncbi.nlm.nih.gov/pubmed/32765397
http://dx.doi.org/10.3389/fneur.2020.00634

Ejemplares similares